Plain-English translation of NCT07333430 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new treatment called HBI0101 CAR-T therapy for patients with multiple myeloma (a blood cancer) that has stopped responding to previous treatments. The researchers are working to find the safest and most effective dose of this medication, which involves re-engineering some of your own immune cells in the laboratory and then infusing them back into your body to fight the cancer.
Multiple myeloma often comes back and becomes resistant to standard drugs after a while, leaving patients with few options. This medication represents a newer approach using your body's own immune system, and this trial will help doctors understand whether it is safe and effective for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. First, researchers will slowly increase the dose of the medication in small groups of patients to find the safest dose. Then, more patients will be treated at that dose to confirm it works. You will receive a single infusion of the engineered immune cells, and the study team will monitor you closely with blood tests, imaging, and hospital visits to watch for side effects and to see if the treatment is helping your cancer.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Israel
Phase
Safety & dosing
Sponsor
Hadassah Medical Organization
Enrollment target
~60 participants
Started
January 2026
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Polina Stepensky, MD
Hadassah Medical Organization
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.